Short answer
Aclaris Therapeutics, Inc. (ACRS) filed an 8-K current report with the SEC on August 6, 2026 reporting Item 2.02 (Results of Operations and Financial Condition), Item EX-99.1 (Exhibit EX-99.1). Item 2.02 contains only filing-incorporation language, with no operating results or financial metrics.
Aclaris Therapeutics, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 2.02 · Results of Operations and Financial Condition
- Item 2.02 contains only filing-incorporation language, with no operating results or financial metrics
- Investors must rely on the referenced exhibit or accompanying earnings release for fiscal 2026 results
Item EX-99.1 · Exhibit EX-99.1
- Q2 net loss widened to $21.5M from $15.4M as R&D rose to $18.1M, reflecting accelerated ATI-052 development
- Cash, equivalents and marketable securities reached $170.6M; subsequent ATM sales added $40.2M from 7.3M shares
- Management expects funding through end-2028, reducing near-term financing risk but highlighting substantial ongoing cash burn
- Three major second-half catalysts: Phase 1b ATI-052 results in asthma and AD, plus Phase 2 bosakitug AD results
- ATI-052 showed potential quarterly dosing; Phase 2b asthma initiation and AD startup activities planned for Q4 2026
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Aclaris Therapeutics, Inc. 8-K filings
Get the next ACRS 8-K as it lands
Follow ACRS for push alerts, or ask the research agent what this filing means.